Rheumatology Network went to Disney World this month, to learn what's most important to pediatric rheumatology in 2014. Watch for our latest and forthcoming reports on important sessions from ACR's PRSYM, including:
(ACR Pediatrics 2014) Children growing into young adults with rheumatic diseases often fail to get the care they need, for numerous complicated reasons. The ACA could change all this, with implications for adult rheumatologists. Here, a brief look at the situation and some solutions.
(ACR Pediatrics 2014) Large research partnerships are proving key to conquering childhood rheumatic diseases like juvenile idiopathic arthritis. To continue the advance, however, larger mergers and newer kinds of data are required.
HAQ, CDAI, RAPID3, DAS28: Which outcome measure should you use to track progress in patients with rheumatoid arthritis? Here, a brief review of their differences, and the arguments for a new paradigm in disease assessment.
(VIDEO) Another dictum from medical school gives way to medical research: Clicking, popping, and locking are not useful for diagnosis and prognosis of suspected meniscal tear in patients over 45. Harvard's Dr. Jeffrey Katz reveals signs that actually are informative in this age group.
(VIDEO) Researchers in Norway used data from an observational study of patients with swollen joints to see how many with early signs of rheumatoid arthritis recovered without any treatment at all, and how quickly.
(ACR Pediatrics 2014) How will the hundreds of new genetic biomarkers being found in rheumatology help us to untangle the web of complex diseases? In a brief podcast, a specialist in both rheumatology and genetics discusses recent and future progress.
(AUDIO) What are immune-like cells doing in the central nervous system? Sending false signals when their controls go awry, as current research implies. Here the lead author of a recent review offers glimpses of a brighter future for relief of chronic pain syndromes.
(AUDIO) A gene defect that causes lupus-like symptoms in a mouse model has turned up as significant in some humans with lupus nephritis, offering a path toward predictive testing. Listen as the lead author reporting this study describes its findings and a timeline toward clinical applications.
More than a third of patients aren't taking DMARDs as guidelines unanimously recommend. Rheumatologist Richard Martin MD reveals insights from new research about why some patients resist the idea, and what you can do to help.